<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for AMPE</title>
    <link />
    <description>Headlines for Ampio Pharmaceuticals, Inc.</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>Ampio Pharma Initiates Phase III, Investors Extend Momentum</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1398731-ampio-pharma-initiates-phase-iii-investors-extend-momentum.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 03 May 2013 09:39:52 GMT</pubDate>
    </item>
    <item>
      <title>Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3528830/ampio-pharmaceuticals-completes-enrollment-in-run-in-spring-study-of-ampion-in-os.aspx</link>
      <author>Benzinga</author>
      <pubDate>Thu, 25 Apr 2013 08:02:33 GMT</pubDate>
    </item>
    <item>
      <title>Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11893972/1/biotech-stock-mailbag-exact-sciences-galena-titan-arena-breakthrough-therapy.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Fri, 12 Apr 2013 06:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1318201-lucrative-amd-and-dme-markets-attract-wall-street-to-regeneron-and-other-players.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 03 Apr 2013 13:43:44 GMT</pubDate>
    </item>
    <item>
      <title>Ampio's Eye Drug Trial Design Won't Pass FDA Muster</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11884765/1/ampios-eye-drug-trial-design-wont-pass-fda-muster.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Tue, 02 Apr 2013 09:00:00 GMT</pubDate>
    </item>
    <item>
      <title>A Peek Into The Market Before The Trading Starts</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3463177/a-peek-into-the-market-before-the-trading-starts.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 02 Apr 2013 07:09:50 GMT</pubDate>
    </item>
    <item>
      <title>Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Kn</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3462939/ampio-receives-fda-acceptance-for-clinical-trial-of-ampion-for-treatment-of-osteo.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 02 Apr 2013 06:05:12 GMT</pubDate>
    </item>
    <item>
      <title>Benzinga's Small Cap Movers for Monday March 11, 2013</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/trading-ideas/long-ideas/13/03/3406329/benzingas-small-cap-movers-for-monday-march-11-2013.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 11 Mar 2013 18:33:52 GMT</pubDate>
    </item>
    <item>
      <title>UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Ampio Pharmaceuticals on Clinical Mileston</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/analyst-ratings/analyst-color/13/03/3385632/update-aegis-capital-reiterates-buy-rating-raises-pt-on-.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 04 Mar 2013 08:09:51 GMT</pubDate>
    </item>
    <item>
      <title>Ampio Pharmaceuticals Begins Clinical Trial of Optina for Diabetic Macular Edema</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/02/3371198/ampio-pharmaceuticals-begins-clinical-trial-of-optina-for-diabetic-macular-edema.aspx</link>
      <author>Benzinga</author>
      <pubDate>Wed, 27 Feb 2013 05:54:19 GMT</pubDate>
    </item>
    <item>
      <title>A Peek Into The Market Before The Trading Starts</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/02/3361792/a-peek-into-the-market-before-the-trading-starts.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 25 Feb 2013 07:13:02 GMT</pubDate>
    </item>
    <item>
      <title>Ampio Pharmaceuticals Announces Phase 3 Ampion Study for Osteoarthritis of the Knee to Include a Dos</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/02/3361435/ampio-pharmaceuticals-announces-phase-3-ampion-study-for-osteoarthritis-of-the-kn.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 25 Feb 2013 05:56:41 GMT</pubDate>
    </item>
    <item>
      <title>Big Pharma Is Knocking At Ampio's Door</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1154231-big-pharma-is-knocking-at-ampio-s-door.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Mon, 04 Feb 2013 10:54:24 GMT</pubDate>
    </item>
    <item>
      <title>Ampio Pharmaceuticals: Overbought And Undercapitalized</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1140321-ampio-pharmaceuticals-overbought-and-undercapitalized.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 29 Jan 2013 11:16:05 GMT</pubDate>
    </item>
    <item>
      <title>A Peek Into The Market Before The Trading Starts</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/01/3261417/a-peek-into-the-market-before-the-trading-starts.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 22 Jan 2013 07:15:46 GMT</pubDate>
    </item>
    <item>
      <title>FDA Accepts Ampio Pharmaceuticals IND for Optina for Treatment of Diabetic Macular Edema</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/01/3261063/fda-accepts-ampio-pharmaceuticals-ind-for-optina-for-treatment-of-diabetic-macula.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 22 Jan 2013 05:50:39 GMT</pubDate>
    </item>
    <item>
      <title>Ampio Stays Calm Ahead Of Further Developments</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1101831-ampio-stays-calm-ahead-of-further-developments.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 09 Jan 2013 02:55:18 GMT</pubDate>
    </item>
    <item>
      <title>Traders Eying Ampio Pharmaceuticals, With 3 Potential Blockbusters In The Red Zone</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1014861-traders-eying-ampio-pharmaceuticals-with-3-potential-blockbusters-in-the-red-zone.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 16 Nov 2012 16:36:20 GMT</pubDate>
    </item>
    <item>
      <title>A Capital-Efficient Prescription For New Drugs: Raghuram "Ram" Selvaraju</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/970391-a-capital-efficient-prescription-for-new-drugs-raghuram-ram-selvaraju.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 01 Nov 2012 16:52:18 GMT</pubDate>
    </item>
    <item>
      <title>Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market?</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/931291-can-ampio-s-new-science-take-a-big-bite-out-of-the-60-billion-anti-inflammatory-market.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 18 Oct 2012 03:07:51 GMT</pubDate>
    </item>
  </channel>
</rss>
